David Cutter

FRCR, DPhil

Clinical Research Fellow (CTSU) and Consultant Clinical Oncologist (Oxford Cancer Centre)

David Cutter studied medicine at the University of Cambridge (1994-2000) and trained in Oncology at the Oxford Cancer Centre. In 2008 he joined CTSU to study for a DPhil on the late cardiovascular effects of cancer treatments. In 2013 he was appointed as a Consultant Clinical Oncologist and continues to work within CTSU upon a programme of work investigating the benefits and risks of cancer treatments.

Recent publications

Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma.
Journal article

Cutter DJ. et al, (2021), J Clin Oncol
Limited-stage diffuse large B-cell lymphoma: current management and challenges.
Journal article

Zhang X-Y. et al, (2021), Br J Haematol
An Excess Mortality Risk Analysis of Proton Beam versus Optimal Photon Radiotherapy for Mediastinal Hodgkin Lymphoma: Who May Benefit Most?
Conference paper

Ntentas G. et al, (2020), INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 108, S140 - S141
Dose-response relationships for radiation-related heart disease: Impact of uncertainties in cardiac dose reconstruction.
Journal article

Ntentas G. et al, (2020), Radiother Oncol
Risk of cerebrovascular disease among 13,457 five-year survivors of childhood cancer: a population based cohort study.
Journal article

Reulen RC. et al, (2020), Int J Cancer

More publications